North America Autologous Stem Cell and Non-Stem Cell Based Therapies Market, By Type (Autologous Stem Cells, Autologous Non-Stem cells), Product (Blood Pressure Monitoring Devices, Pulmonary Pressure Monitoring Devices, Intracranial Pressure Monitoring Devices), Applications (Neurodegenerative Disorders, Autoimmune Diseases, Cancer and Tumors, Cardiovascular Diseases), End-User (Hospitals and Ambulatory Surgical Centers) – Industry Trends and Forecast to 2030.
North America Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis and Size
The North America autologous stem cell and non-stem cell based therapies market is expected to gain market growth due to the growing recognition of the medicinal capacity of stem cells in efficient disease management, contributing to driving the growth of the autologous stem cell and non-stem cell based therapies market. Additionally, cancer and diabetes incidence in all age communities and the growth of progressive genome-based cell analysis techniques also heighten the market's overall growth. However, increasing demand for advanced wound closure materials and side effects from surgical sutures are estimated to obstruct the market’s growth.
Data Bridge Market Research analyses that the North America autologous stem cell and non-stem cell based therapies market is expected to undergo a CAGR of 15.21% during the forecast period. This indicates that the market value. “Hospitals” dominates the End-User segment of the autologous stem cell and non-stem cell based therapies market owing to the growing demand for autologous stem cell and non-stem cell based therapies in hospitals. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
North America Autologous Stem Cell and Non-Stem Cell Based Therapies Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2014-2020) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Type (Autologous Stem Cells, Autologous Non-Stem cells), Product (Blood Pressure Monitoring Devices, Pulmonary Pressure Monitoring Devices, Intracranial Pressure Monitoring Devices), Applications (Neurodegenerative Disorders, Autoimmune Diseases, Cancer and Tumors, Cardiovascular Diseases), End-User (Hospitals and Ambulatory Surgical Center) |
|
Countries Covered |
U.S., Canada and Mexico |
|
Market Players Covered |
Takeda Pharmaceutical Company Limited (Japan), Regeneus Ltd (Australia), Regenexx, Orgenesis Inc. (U.S.), NEOSTEM(U.S.), Genesis BioPharma Services. (U.S.), chimerictherapeutics(Australia), Regrow Biosciences Pvt Ltd.(India), viriontx(U.S.), Mesoblast Ltd(Australia), among others |
|
Market Opportunities |
|
Market Definition
Autologous stem cell transplantation, also called autogenous stem-cell transplantation, is a medical procedure promoting the repair response of the diseased. Under this, the individual's undivided stem cells are collected and then transplanted back into the person after the therapy. The therapies are generally performed using hematopoietic stem cells. Autologous and non-systemic stem cell therapies treat cardiovascular, cancer, autoimmune, neurodegenerative, and parasitic diseases.
North America Autologous Stem Cell and Non-Stem Cell Based Therapies Market Dynamics
Drivers
- Increasing prevalence of chronic diseases
This is attributable to the increased adoption of immunotherapy for the treatment of cancer across the globe. People are increasingly adopting targeted therapy for treatment as they are more convenient and effective. The growing recognition of the medicinal capacity of stem cells in efficient disease management contributes to driving the growth of the autologous stem cell and non-stem cell based therapies market. Additionally, cancer and diabetes incidence in all age communities and the growth of progressive genome-based cell analysis techniques also heighten the market's overall growth.
- Rising geriatric population
Expanding geriatric population worldwide is predicted to favor cytokine release syndrome drug demand as this population is more prone to chronic diseases. The number of persons above 65 years is projected to double in the coming years.
As people age, there is an increase in the occurrence of degenerative diseases, which could be treated with the help of stem cell therapy. The growing older population is expected to increase the demand for innovative disease treatment procedures, thereby accelerating the growth of the global autologous stem cell and non-stem cell-based therapies market.
- Increasing research and development
Stem cell technology is a speedily developing technology that plays a major role in regenerative medicine. It also serves the disciplines of tissue engineering, developmental cell biology, cellular therapeutics, gene therapy, chemical biology, and nanotechnology. Stem cells can replace the cells and tissues to treat various conditions, including spinal cord injury, arthritis, and Parkinson’s disease. According to the CDC, in October 2021, around 63 million people in the United States were estimated to have been affected by arthritis, with the numbers estimated to rise to 78 million by 2040. There has been an increase in research on using stem cells as experimental treatments for arthritis to help regrow cartilage. The applications of stem cell technologies in such treatments increased the overall adoption rate of these technologies worldwide. The advantage of an autologous stem cell transplant is that one gets one’s cells back, and there is no risk of rejection from the individual's immune system. Such research studies are expected to contribute to the market's growth over the forecast period.
Opportunities
- Rising healthcare expenditure
The amount of money a country uses on its healthcare and its growth rate over time is inclined by a wide variety of economic and social factors, including the financing arrangements and structure of the health system organization. In particular, there is a strong association between the whole income level and how much the population of that country spends on health care.
According to the statistics mentioned in the Harvard Business Review, in the U.S. healthcare system, around USD 1.0 trillion is spent on healthcare delivery. According to these figures, preventable medical errors are the third leading cause of death in the U.S. Electronic Medical Records (EMR) can help correct these systemic errors.
Healthcare expenditure has increased across developed countries and emerging economies as the disposable income of people are growing. Moreover, to accomplish the population requirements, government bodies and healthcare organizations in different regions are taking the initiative by virtue of accelerating healthcare expenditure. The rise in healthcare expenditure helps organizations improve their facilities and equipment, including medical carts.
- Strategic initiatives by key market players
Strategic initiatives such as acquisition, partnership, contract agreement, and conference participation allow their customer base to flourish. Moreover, through such initiative strategies, both companies expand their reach through new geographic or industry markets, access to new products or services, or new types of customers. Both market players open the door to additional or new resources such as technology and talent.
Restraints/Challenges
On the other hand, increasing demand for advanced wound closure materials and side effects from surgical sutures are the major factors among others are expected to obstruct market growth. Moreover, the high cost of autologous cellular therapies and the lack of skilled professionals will further challenge the North America autologous stem cell and non-stem cell based therapies market in the forecast period of 2023-2030.
This autologous stem cell and non-stem cell based therapies market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the autologous stem cell and non-stem cell based therapies market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.
Recent Development
- In March 2021, the US FDA approved Novadip’s Investigational New Drug (IND) application for its autologous cell therapy product NVD‑003 for treating congenital pseudarthrosis of the tibia.
North America Autologous Stem Cell and Non-Stem Cell Based Therapies Market Scope
North America Autologous Stem Cell and Non-Stem Cell Based Therapies Market is segmented on the basis of type, product, applications and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Autologous Stem Cells
- Autologous Non-Stem cells
Product
- Blood Pressure Monitoring Devices
- Pulmonary Pressure Monitoring Devices
- Intracranial Pressure Monitoring Devices
Application
- Neurodegenerative Disorders
- Autoimmune Diseases
- Cancer and Tumors
- Cardiovascular Diseases
End-User
- Hospitals
- Ambulatory Surgical Center
North America Autologous Stem Cell and Non-Stem Cell Based Therapies Market Regional Analysis/Insights
The North America autologous stem cell and non-stem cell based therapies market is analysed and market size insights and trends are provided by country, type, product, applications and end-user as referenced above.
The countries covered in the autologous stem cell and non-stem cell based therapies market report are U.S., Canada and Mexico.
The U.S. is expected to dominate the North America autologous stem cell and non-stem cell based therapies market due to the availability of funds from various organizations within the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The North America autologous stem cell and non-stem cell based therapies market also provides you with detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kind of products for autologous stem cell and non-stem cell based therapies market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the autologous stem cell and non-stem cell based therapies market. The data is available for the historic period 2015-2020.
Competitive Landscape and North America Autologous Stem Cell and Non-Stem Cell Based Therapies Market Share Analysis
The North America Autologous Stem Cell and Non-Stem Cell Based Therapies Market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to autologous stem cell and non-stem cell based therapies market.
Some of the major players operating in the North America autologous stem cell and non-stem cell based therapies market are:
- Takeda Pharmaceutical Company Limited (Japan)
- Regeneus Ltd (Australia)
- Regenexx, Orgenesis Inc. (U.S.)
- NEOSTEM(U.S.)
- Genesis BioPharma Services. (U.S.)
- chimerictherapeutics(Australia)
- Regrow Biosciences Pvt Ltd.(India)
- viriontx(U.S.)
- Mesoblast Ltd(Australia),
SKU-
